# **Screening Libraries**

# **Product** Data Sheet

# NSC 185058

Cat. No.: HY-125169 CAS No.: 39122-38-8 Molecular Formula:  $C_{11}H_{9}N_{3}S$ Molecular Weight: 215.27

Target: Autophagy; Atg4 Pathway: Autophagy

Storage: 4°C, protect from light

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO : ≥ 125 mg/mL (580.67 mM)

\* "≥" means soluble, but saturation unknown.

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 4.6453 mL | 23.2266 mL | 46.4533 mL |
|                              | 5 mM                          | 0.9291 mL | 4.6453 mL  | 9.2907 mL  |
|                              | 10 mM                         | 0.4645 mL | 2.3227 mL  | 4.6453 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (9.66 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (9.66 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (9.66 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

| Description               | NSC 185058 is an inhibitor of ATG4B, a major cysteine protease. Inhibition of ATG4B using NSC 185058 markedly attenuates autophagic activity $^{[1]}$ .   |
|---------------------------|---|
| IC <sub>50</sub> & Target | $ATG4B^{[1]}$ Autophagy $^{[1]}$  |
| In Vivo                   | NSC185058 is an ATG4B antagonist. ATG4B stimulates autophagy by promoting autophagosome formation through reversible modification of ATG8. Inclusion of the ATG4B inhibitor NSC185058 enhances the anti-tumor activity of radiation |

therapy (RT). NSC185058 decreases glioblastoma (GBM) cell tumorigenicity, and enhances the anti-tumor activity of RT when applied to orthotopic GBM xenograft models $^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. Huang T, et al. MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell. 2017 Dec 11;32(6):840-855.e8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com